10-K: MiniMed Group Reports Strong FY26 Results, Driven by CGM Growth

MiniMed Group, Inc. announced its fiscal year 2026 results, showcasing a 14% increase in net sales to $3.1 billion, primarily fueled by robust international growth in its CGM segment.

Summary

• MiniMed Group, Inc. reported net sales of $3.1 billion for fiscal year 2026, a 14% increase from $2.7 billion in fiscal year 2025.
• International sales grew by 21% to $2.185 billion, while U.S. sales increased by 2% to $917 million.
• The company experienced a net loss of $317 million in fiscal year 2026, compared to a net loss of $198 million in fiscal year 2025.
• Adjusted EBITDA decreased to $202 million in fiscal year 2026 from $253 million in fiscal year 2025.
• The MiniMed 780G system continues to be a key driver, with a global CGM attachment rate increasing to 66%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with strong revenue growth and product innovation, but tempered by an increased net loss and decreased Adjusted EBITDA, indicating areas for operational improvement.

Positives

• Net sales increased by 14% year-over-year, reaching $3.1 billion.
• International sales showed strong growth of 21%, indicating successful global expansion.
• CGM sales increased by 18%, driven by a higher global CGM attachment rate of 66%.
• The company launched the MiniMed Flex insulin pump in the U.S. in June 2026, following FDA clearance in March 2026.
• Partnership with Abbott was extended to commercialize dual glucose-ketone sensors.
• The company ended the fiscal year with $298 million in cash and cash equivalents.

Negatives

• The company reported a net loss of $317 million for fiscal year 2026, an increase from the $198 million net loss in fiscal year 2025.
• Adjusted EBITDA decreased by 20% to $202 million in fiscal year 2026.
• U.S. pump sales declined by 7% due to timing effects related to the MiniMed Flex launch and delayed Simplera CGM launch.
• Cost of products sold increased by 20%, outpacing net sales growth, partly due to asset write-offs and warranty expenses.
• The company recognized a one-time charge of $157 million related to future minimum royalty payment obligations under a research and development funding arrangement with Blackstone.

Risks

• Intense competition in the diabetes management market, with potential for competitors to develop superior products.
• Pricing pressure on CGM products, particularly in international markets.
• Delays in the development or launch of new products, including regulatory approvals.
• Reliance on sole suppliers for critical components, posing risks of shortages or price fluctuations.
• Potential for cybersecurity threats to disrupt operations and compromise data.
• Changes in government reimbursement policies and healthcare regulations could adversely affect sales.
• The company's limited history as a standalone public company and the costs associated with operating independently.
• Medtronic's significant ownership stake and potential influence over the company's direction.
• The possibility of future distributions or sales of Medtronic's shares impacting the company's stock price.
• The company's dependence on intellectual property rights and the risk of infringement or litigation.

Future Outlook

The company expects continued growth driven by the adoption of Smart Dosing solutions like AID systems, expansion of its product pipeline including the MiniMed Fit patch pump and Vivera dosing algorithm, and strategic partnerships. However, it anticipates ongoing pricing pressure on CGMs and potential impacts from regulatory changes and competition.

Management Comments

• We believe our solutions have demonstrated superiority over the current standard of care of administering insulin through MDI manually with only standalone blood glucose monitoring or CGM sensor.
• We believe our pipeline is at a critical turning point where our next-generation AID system will create significant competitive differentiation to fulfill our mission of safely and effectively automating diabetes management to deliver a hands-off patient experience.
• We aim to generate sustainable and profitable growth through execution of our corporate strategies.

Industry Context

StockSavvy.ai notes that MiniMed Group's performance reflects the broader trend in the diabetes technology market towards more integrated and automated solutions like AID systems, which are gaining traction due to their ability to improve clinical outcomes and reduce patient burden. The company's focus on innovation and expanding its product portfolio aligns with industry demands for user-friendly and effective diabetes management tools.

Comparison to Industry Standards

• MiniMed 780G system's Time in Range (TIR) performance of 72.1% for all users and 77.5% for ROS users is presented as superior to competing systems based on real-world data and meta-analyses.
• The company highlights that its MiniMed 780G system achieved a 10 percentage point higher TIR than Omnipod 5 in a meta-analysis of 32 RCTs.
• User satisfaction ratings for the MiniMed 780G system in the U.S. were 53% in Q2 2025, outperforming competitors like Tandem t:slim X2 (47%), Tandem Mobi (48%), Insulet Omnipod 5 (37%), and Beta Bionics iLet (34%).

Legal Proceedings

• The company is involved in ongoing lawsuits in the U.S. and Canada related to alleged personal injuries, including deaths, caused by Series 600 insulin pumps with defective clear retainer rings. A trial resulted in a verdict on June 17, 2026, with no damages awarded for some plaintiffs and $253,000 awarded for one plaintiff, subject to reduction.
• A purported class action lawsuit was filed in Canada in 2021 concerning similar allegations.
• The company is aware of inquiries from state attorneys general regarding its Series 600 insulin pumps.
• A former sales representative filed a qui tam lawsuit alleging violations of the False Claims Act in connection with sales of certain insulin pump products from 2007 to 2014.

Related Party Transactions

• The company entered into a global integration, supply, and distribution agreement with Abbott, which was amended to extend the partnership for dual glucose-ketone sensors.
• The company has research and development funding arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C. for product development.
• Various separation agreements with Medtronic govern the allocation of assets and liabilities, including transition services, tax matters, employee matters, intellectual property licenses, and manufacturing and supply agreements.

Stakeholder Impact

• Shareholders may experience dilution from future issuances of common stock or convertible debt.
• Medtronic's significant ownership (90%) means it can control company direction, potentially impacting other stockholders' influence.
• Customers (people with diabetes) benefit from advanced technology aimed at improving glycemic control and reducing management burden.
• Healthcare professionals (HCPs) are key partners in product adoption and receive support through training and data platforms.
• Payors (insurance providers) are critical for reimbursement, and changes in policies could impact product accessibility and company revenue.

Next Steps

• Continue to drive adoption of AID across the addressable market and additional population segments.
• Increase global CGM Attachment Rate with the next-generation Simplera Sync CGM sensor.
• Expand the addressable market for MiniMed 780G through expanded indication labeling.
• Drive momentum with MiniMed Go, the next-generation Smart MDI system solution.
• Globally introduce new insulin patch pumps and the next-generation Vivera dosing algorithm, subject to regulatory approval.
• Continue to pursue attractive strategic collaboration opportunities and tuck-in acquisitions.

Key Dates

Recommendation

While MiniMed Group shows strong revenue growth and product innovation, the increased net loss, decreased Adjusted EBITDA, and significant one-time charges indicate operational challenges. The company's market position is strong, but the financial performance warrants a cautious 'hold' until profitability improves and the impact of new product launches is fully realized.

Keywords

MiniMed Group, SEC Filing, Form 10-K, Annual Report, Diabetes Management, Insulin Pump, CGM, AID System, Smart MDI, MiniMed 780G, MiniMed Flex, Financial Results, Medical Technology